- Three international patent applications were published describing spray-dried and powder formulation approaches enabling nasal and pulmonary delivery of GLP-1 therapies (e.g., semaglutide).
- Preclinical PK studies on liquid and powder semaglutide formulations showed up to 10× systemic Cmax versus a comparable oral dose in a preclinical model.
- Development work was performed by Aptar Pharma Services teams in the UK, US and France, with additional data planned for scientific conferences and peer-reviewed publications in 2026–2027.
Patent filings
Three international patent applications were published covering formulation approaches to enable nasal and pulmonary delivery of GLP‑1 therapies, including spray‑dried and powder processing technologies for intranasal and pulmonary administration.
Formulation and preclinical data
Preclinical PK studies on liquid and powder semaglutide formulations demonstrated up to 10× higher systemic Cmax versus a comparable oral dose in a preclinical model, providing preclinical proof‑of‑concept for the formulation and device‑enabled approaches.
Development work and capabilities
Development was performed by Aptar Pharma Services teams in the UK, US and France, leveraging formulation science, analytical characterization and device compatibility expertise for orally inhaled and nasal drug products (OINDPs).
Biologics compatibility program
The GLP‑1 work is part of a broader program assessing interactions between complex biologics (nucleic acids, proteins) and nanoparticle‑based delivery systems with nasal and pulmonary delivery platforms across multiple formulation and device formats.
Next steps and dissemination
Additional data are expected to be presented at scientific conferences and submitted to peer‑reviewed journals in 2026–2027, subject to completion of ongoing research and publication timelines.
